Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19

NCT05689827 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Asthenia
COVID-19

Interventions

DRUG: Ethyl methyl hydroxypyridine succinate + Meldonium
DRUG: Placebo

Sponsor

Promomed, LLC